OBJECTIVE: To observe the short-term effect and adverse reaction of Nimotuzumab in combination with chemotherapy on advanced esophageal squamous cell carcinoma (ESCC). METHOD: 19 patients were treated with the following protocol: Nimotuzumab 400mg/time/week in the 1(st) week, 200mg/time/week from the 2(nd) to 8(th) week, intravenous drip (IVD); Cisplatin 80 mg/m(2), IVD, 4 weeks a cycle and repeated again; 5-FU 750 mg/m(2), continuous 24-hours pump-in × 5 days, 4 weeks a cycle and repeated again. RESULT: 16 of all 19 patients can be evaluated. After treatment, RP is 42.1% (95% CI, 19.9-64.3%) and DCR is 68.4%; the main side effects include arrest of bone marrow, gastrointestinal reactions, asthenia, etc. CONCLUSION: Nimotuzumab in combination with cisplatin/5-FU regimens in patients with advanced ESCC is safe and effective, which deserves a further expanded sample research.
OBJECTIVE: To observe the short-term effect and adverse reaction of Nimotuzumab in combination with chemotherapy on advanced esophageal squamous cell carcinoma (ESCC). METHOD: 19 patients were treated with the following protocol: Nimotuzumab 400mg/time/week in the 1(st) week, 200mg/time/week from the 2(nd) to 8(th) week, intravenous drip (IVD); Cisplatin 80 mg/m(2), IVD, 4 weeks a cycle and repeated again; 5-FU 750 mg/m(2), continuous 24-hours pump-in × 5 days, 4 weeks a cycle and repeated again. RESULT: 16 of all 19 patients can be evaluated. After treatment, RP is 42.1% (95% CI, 19.9-64.3%) and DCR is 68.4%; the main side effects include arrest of bone marrow, gastrointestinal reactions, asthenia, etc. CONCLUSION:Nimotuzumab in combination with cisplatin/5-FU regimens in patients with advanced ESCC is safe and effective, which deserves a further expanded sample research.
Authors: Yi-Jen Chen; Kemp H Kernstine; Stephen Shibata; Dean Lim; David D Smith; Martin Tang; An Liu; Richard D Pezner; Jeffrey Y C Wong Journal: J Thorac Dis Date: 2009-12 Impact factor: 2.895
Authors: H Bleiberg; T Conroy; B Paillot; A J Lacave; G Blijham; J H Jacob; L Bedenne; M Namer; P De Besi; F Gay; L Collette; T Sahmoud Journal: Eur J Cancer Date: 1997-07 Impact factor: 9.162
Authors: K Hayashi; N Ando; H Watanabe; H Ide; K Nagai; N Aoyama; W Takiyama; K Ishida; K Isono; H Makuuchi; M Imamura; M Shinoda; S Ikeuchi; T Kabuto; H Yamana; H Fukuda Journal: Jpn J Clin Oncol Date: 2001-09 Impact factor: 3.019
Authors: David R Ferry; Mark Anderson; Kate Beddard; Simon Tomlinson; Paul Atherfold; Jolanta Obszynska; Rebecca Harrison; Janusz Jankowski Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: L Gibault; J-P Metges; V Conan-Charlet; P Lozac'h; M Robaszkiewicz; C Bessaguet; N Lagarde; A Volant Journal: Br J Cancer Date: 2005-07-11 Impact factor: 7.640
Authors: J Jia; Y Cui; M Lu; X Wang; Jie Li; Jian Li; Y Li; X Zhang; J Gao; J Zhou; Z Lu; J Gong; J Yu; Z Sun; C Liu; L Shen; X Zhang Journal: Clin Transl Oncol Date: 2015-10-12 Impact factor: 3.405
Authors: Ming Lu; Xicheng Wang; Lin Shen; Jun Jia; Jifang Gong; Jie Li; Jian Li; Yan Li; Xiaotian Zhang; Zhihao Lu; Jun Zhou; Xiaodong Zhang Journal: Cancer Sci Date: 2016-03-28 Impact factor: 6.716